By Fineline Cube 
3SBio Inc. (HKG: 1530) and Hangzhou Tigermed Consulting Co., Ltd. (SHE: 300347, HKG: 3347), China’s leading Contract Research Organization (CRO), have announced a comprehensive strategic partnership spanning innovative drug research and development (R&D), clinical services, and industrial investment. The collaboration aims to establish a new ecosystem for pharmaceutical innovation cooperation through synergistic integration of both companies’ core competencies.
Partnership Framework
| Component | 3SBio Contribution | Tigermed Contribution |
|---|---|---|
| R&D Expertise | Innovative drug R&D capabilities and product pipelines | Clinical development design and regulatory strategy |
| Operational Resources | Industrial resources and manufacturing infrastructure | Global multicenter trial execution capabilities |
| Investment Focus | Pipeline asset development and commercialization | Investment incubation and technology fund access |
| Strategic Evolution | From “point-based collaboration” to “full-chain coordination” | Comprehensive coverage across R&D-to-industrialization continuum |
Governance Structure & Implementation
- Joint R&D Management Committee: Established to coordinate execution of key strategic projects and resource allocation
- Dedicated Project Teams: Cross-functional teams formed to jointly conduct R&D planning and clinical trial design
- Funding Collaboration: Joint applications for national and provincial technology innovation fund projects
- Timeline: Initial projects to commence Q3 2026, with full-chain coordination model implementation targeted for 2027
The partnership represents a significant evolution in China’s biopharmaceutical collaboration model, moving beyond traditional CRO-client relationships toward integrated innovation ecosystems that span the entire drug development lifecycle.
Strategic Rationale
For 3SBio Inc.
- Pipeline Acceleration: Leverages Tigermed’s global clinical trial expertise to expedite development timelines for innovative assets
- Regulatory Optimization: Gains access to Tigermed’s established regulatory filing capabilities for domestic and international markets
- Resource Efficiency: Reduces operational burden through shared infrastructure and expertise across the development continuum
- Innovation Funding: Enhanced access to government and private innovation funding through joint applications
For Hangzhou Tigermed
- Asset Depth: Secures long-term pipeline visibility through strategic partnership with established biopharmaceutical innovator
- Service Integration: Expands beyond traditional CRO services to include investment incubation and industrialization support
- Market Differentiation: Establishes leadership position in China’s evolving “full-chain” pharmaceutical innovation model
- Revenue Diversification: Creates opportunities for equity participation and milestone-based compensation beyond fee-for-service
Market Context & Industry Implications
- China Biopharma Landscape: Domestic innovative drug development accelerating, with 42 Class 1 new drugs approved in 2025 (up 35% YoY)
- CRO Market Evolution: Traditional service providers increasingly transitioning to strategic partners with integrated capabilities
- Government Support: Strong policy backing for “industry-academia-research” collaboration models through National Key R&D Programs
- Investment Climate: Growing availability of specialized funds targeting late-stage preclinical and early clinical assets
“This partnership transcends conventional collaboration boundaries,” said Dr. Wenbo Fu, Chairman and CEO of 3SBio. “By integrating our innovative R&D capabilities with Tigermed’s world-class clinical development expertise, we’re creating a new paradigm for pharmaceutical innovation that will accelerate the delivery of breakthrough therapies to patients.”
Forward-Looking Statements
This brief contains forward-looking statements regarding partnership implementation, project timelines, and strategic objectives. Actual results may differ due to risks including regulatory changes, competitive dynamics, funding availability, and execution challenges in complex multi-party collaborations.-Fineline Info & Tech